The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score 2.37 — grey zone — between safe and distressedWatch
- Earnings-manipulation signal · Beneish M -3.29 — no flag raisedOK
- Earnings quality 86/100 — accruals in line with cashOK
Where the revenue comes from
Fiscal 2025, as Immunocore Holdings plc reports it. History and quarterly detail are in the app.
- Revenue from sale of therapies, net$400.0M
Leadership changes
From Immunocore Holdings plc's own filings, the day they're filed.
- Tina St · departureeff. 2026-05-26
- Ranjeev Krishana Resignation On · directors · departureeff. 2025-11-26
- Ranjeev Krishana · directors · departureeff. 2025-11-26
Latest filings
- 8-K · Company announcement2026-05-27
- 10-Q · Quarterly report2026-05-06
- 8-K · Company announcement2026-05-06
- DEF 14A · Annual proxy (pay & governance)2026-04-16
- 8-K · Company announcement2026-02-25
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about Immunocore Holdings plc, every answer cited🔒
- The Intelligence Brief — added when Immunocore Holdings plc's brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.